wild casino download

Future Vision II Acquisition Corp. Announces Entering into Amendment No. 1 to Merger Agreement with Viwo Technology Inc.NoneRussian Hackers Breached a DC-Area Organization Through a Neighbor’s Wi-Fi. Here’s How to Make Yours Harder to CrackSolarEdge Technologies, Inc. SEDG shares are trading higher. The company announced plans to cease all activities of its energy storage division and reduce its workforce by about 500 employees. Here’s what you need to know . What To Know: In a new press release Wednesday, SolarEdge stated it was shutting down its energy storage division to prioritize its solar operations. The move will result in a workforce reduction of approximately 500 employees, largely located in South Korea. The closure is expected to result in quarterly operating expense savings of approximately $7.5 million, with full savings anticipated to be realized by the second half of 2025. In addition, the company plans to sell assets related to its storage division, including manufacturing facilities for battery cells and packs. “The decision to close our Energy Storage division was the result of a thoughtful analysis of our portfolio of businesses and product lines, industry trends, and the competitive environment,” said interim CEO Ronen Faier. “The measures also represent continued execution of two of our main priorities: financial stability through cost reduction, return to cash flow positivity and profitability; and focus on our core business lines of solar, PV-attached storage and energy management capabilities. I wish to thank our Energy Storage division employees for all of their efforts in building this business.” See Also: This Is What Whales Are Betting On Zscaler SEDG Price Action: At the time of writing, SolarEdge stock was up 8.69% at $14.88, according to data from Benzinga Pro . Image: via Pixabay © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Continues IPOS Corporate Partnership as Emerald-Level Sponsor WARSAW, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics” or the "Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its continued support of the event as an Emerald-Level sponsor. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons. Over 500 pediatric orthopedic surgeons are registered to attend the meeting from December 3-7, in Orlando, Florida. "This year marks the 20 th Annual IPOS meeting, and I couldn't be prouder of our partnership with this surgical society, and our participation in this meeting,” said David Bailey, President and CEO of OrthoPediatrics. "IPOS is a great educational opportunity for early career surgeons, and our team is excited to connect with customers and share hands-on learning experiences with our new and innovative products. I'm especially excited to introduce our new Enabling Technology division as well as highlight all the great work we are doing in non-operative care through OPSB Specialty Bracing.” In addition to the exhibition booths (#1 - 3), wherein the Company will highlight their full suite of products, and feature its new Enabling Technology division with 7D, 3-D Side and the new Specialty Bracing division (OPSB), the Company is hosting several educational experiences for surgeons and other allied health professionals. OrthoPediatrics IPOS 2024 Events include: Pre-course Wednesday, December 4, 2024, 4:05pm ET Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. Investor Contact Philip Trip Taylor Gilmartin Group [email protected] 415-937-5406

AMESBURY, Mass. , Dec. 2, 2024 /PRNewswire/ -- Provident Bancorp, Inc. (the "Company") (Nasdaq:PVBC), the holding company for BankProv (the "Bank"), today announced that its Board of Directors has adopted a new stock repurchase program. Under the repurchase program, the Company may repurchase up to 883,366 shares of its common stock, or approximately five percent of the current outstanding shares. The repurchase program was adopted following the receipt of non-objection from the Federal Reserve Bank of Boston . The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission. Repurchases will be made at management's discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b -18 of the Securities and Exchange Commission and other applicable legal requirements. The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares. About Provident Bancorp, Inc. Provident Bancorp, Inc. (NASDAQ:PVBC) is the holding company for BankProv, a full-service commercial bank headquartered in Massachusetts . With retail branches in the Seacoast Region of Northeastern Massachusetts and New Hampshire , as well as commercial banking offices in the Manchester / Concord market in Central New Hampshire , BankProv delivers a unique combination of traditional banking services and innovative financial solutions to its markets. Founded in Amesbury, Massachusetts in 1828, BankProv holds the honor of being the 10th oldest bank in the nation. The Bank insures 100% of deposits through a combination of insurance provided by the Federal Deposit Insurance Corporation (FDIC) and the Depositors Insurance Fund (DIF). For more information, visit bankprov.com . Forward-Looking Statements This news release may contain certain forward-looking statements, such as statements of the Company's or the Bank's plans, objectives, expectations, estimates and intentions. Forward-looking statements may be identified by the use of words such as, "expects," "subject," "believe," "will," "intends," "may," "will be" or "would." These statements are subject to change based on various important factors (some of which are beyond the Company's or the Bank's control), and actual results may differ materially. Accordingly, readers should not place undue reliance on any forward-looking statements (which reflect management's analysis of factors only as of the date on which they are given). These factors include: general economic conditions; interest rates; inflation; levels of unemployment; legislative, regulatory and accounting changes; monetary and fiscal policies of the U.S. Government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve Bank; deposit flows; our ability to access cost-effective funding; changes in liquidity, including the size and composition of our deposit portfolio and the percentage of uninsured deposits in the portfolio; changes in consumer spending, borrowing and savings habits; competition; our ability to successfully shift the balance sheet to that of a traditional community bank; real estate values in the market area; loan demand; the adequacy of our level and methodology for calculating our allowance for credit losses; changes in the quality of our loan and securities portfolios; the ability of our borrowers to repay their loans; our ability to retain key employees; failures or breaches of our IT systems, including cyberattacks; the failure to maintain current technologies; the ability of the Company or the Bank to effectively manage its growth; global and national war and terrorism; the impact of the COVID-19 pandemic or any other pandemic on our operations and financial results and those of our customers; and results of regulatory examinations, among other factors. The foregoing list of important factors is not exclusive. Readers should carefully review the risk factors described in other documents that the Company files from time to time with the Securities and Exchange Commission, including Annual and Quarterly Reports on Forms 10-K and 10-Q, and Current Reports on Form 8-K. Investor contact: Joseph Reilly President and Chief Executive Officer Provident Bancorp, Inc. jreilly@bankprov.com View original content to download multimedia: https://www.prnewswire.com/news-releases/provident-bancorp-inc-adopts-stock-repurchase-program-302320082.html SOURCE Provident Bancorp, Inc.General Motors is selling its stake in the nearly completed Ultium Cells battery cell plant in Lansing, Michigan, to its joint venture partner LG Energy Solution (LGES). GM’s step back from the factory comes amid weakening electric vehicle demand and the potential rollback of Biden administration incentives to produce clean energy domestically. GM and LGES initially teamed up in 2019 to form a joint venture to mass-produce battery cells for electric vehicles. Since then, the two have poured billions into three factories: The Lansing facility that LGES is acquiring; a Spring Hill, Tennessee , facility that started production in 2024; and a Lordstown, Ohio, factory that has been producing battery cells since 2022. The cells produced at the Ohio and Tennessee plants power vehicles like the Chevrolet Silverado EV, GMC Sierra EV, Cadillac LYRIQ, Chevrolet Blazer EV, and Chevrolet Equinox EV, as well as the GMC Hummer EV pickup and SUV. In October, GM dropped the Ultium battery brand name as part of a move to embrace new types of cells and chemistries, like lithium iron phosphate (LFP) batteries. GM helped set the stage for a movement among automakers and battery manufacturers to onshore battery production after the COVID-19 pandemic. President Joe Biden’s Inflation Reduction Act, which he signed in August 2022, included incentives geared toward helping the U.S. reduce reliance on China for batteries and served as a catalyst for a wave of new battery projects . Aside from LGES, GM also announced a joint venture with Samsung SDI to build a new battery plant in the United States in April 2023 and is working with a handful of startups dedicated to fostering new battery technology. The news of GM’s nonbinding agreement with LGES comes a few months after reports that GM and LGES were slowing the buildout of the Lansing plant, which was expected to start production in 2025. LGES did not respond in time to TechCrunch to confirm if that timeline is still accurate, nor whether the company still expects the plant’s capacity to reach 45 GWh at peak production. Neither company shared the acquisition price, but a spokesperson from GM said the company expects to recoup its initial investment. In a statement, GM said it expects the remaining two plants will be sufficient to meet current demand. GM didn’t share how much LGES is buying the factory for, but a spokesperson for the company said GM expects to recoup its initial investment. GM and LGES initially announced a $2.6 billion investment into the plant, but it’s not clear how much each company has spent. GM also announced Monday that it would work with LGES to jointly develop prismatic battery cells. Levy declined to share whether those cells would be produced at one of the remaining joint venture sites, or if they’ll be manufactured in a yet-to-be-announced facility. At the Ohio and Tennessee plants, GM and LGES have focused on making pouch cells, which have the benefit of being more affordable and flexible in shape. Prismatic cells, while heavier and more expensive, have a higher energy density, longer life cycle, and better heat management.

Companies that spend large sums in the United States will be fast-tracked for environmental and other kinds of permits, President-elect Donald Trump said Tuesday. Trump announced his plan in a social media post , saying any individual or company that invests $1 billion or more in the U.S. "will receive fully expedited approvals and permits, including, but in no way limited to, all Environmental approvals." "GET READY TO ROCK!!!" Trump added. Trump campaigned on reviving American manufacturing. He has promised tariffs on goods produced overseas, including targeting some of the country's major trading partners. He argues the move could make U.S. companies more competitive and spur foreign companies to produce more goods in America. Tariffs could also drive up the cost of some products, though, contributing to inflation. Now, Trump is proposing to mix the threat of tariffs with the lure of easing regulatory burdens. Republicans have long raised concerns about overregulation, and one of Trump's signature campaign promises was clearing the way for the energy industry in America. But speeding up permitting could be met with opposition from groups worried about environmental impacts, public safety, health and other issues raised by some industries. And it's unclear how much, and how quickly, Trump could overhaul longstanding permitting practices at federal agencies. Trump's proposal to incentivize American investments with faster permitting comes as he is poised to make sweeping changes to the federal government. Trump's new Department of Government Efficiency (DOGE) led by billionaire entrepreneurs Elon Musk and Vivek Ramaswamy is targeting government regulations and spending. Musk praised Trump's new proposal Tuesday, sharing his social media post on X and writing "This is awesome." Musk's companies, such as Tesla and SpaceX, are heavily regulated.NBA memo to players urges increased vigilance regarding home security following break-ins

LAUSANNE , Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland , and has operations in London and New Jersey . For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn . ZYNLONTA ® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA ® revenue in the United States ; the ability of our partners to commercialize ZYNLONTA ® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA ® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS: Investors Marcy Graham ADC Therapeutics Marcy.Graham@adctherapeutics.com +1 650-667-6450 Media Nicole Riley ADC Therapeutics Nicole.Riley@adctherapeutics.com +1 862-926-9040 View original content to download multimedia: https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302320100.html SOURCE ADC Therapeutics SANoneNBA memo to players urges increased vigilance regarding home security following break-ins

Christmas in Japan with Kids